At the recent American Academy of Dermatology (AAD) annual meeting, new phase III data from the LATITUDE-PsO-3001 and ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

The FDA has approved Dupixent for children aged 2 to 11 with chronic spontaneous urticaria (CSU) who do not respond to H1 antihistamines, the first biologic therapy for this age group. The decision ...

The expanded approval was based on data extrapolated from Study A, B, and C of the LIBERTY-CUPID program and supportive pharmacokinetics data from the single-arm CUPIDKids study.

Biologic drugs can be joint savers for rheumatoid arthritis (RA). But even these powerful medications don't always guarantee relief from pain and stiffness. Sometimes the first biologic you try ...

A handful of antibody-based extracellular targeted protein degraders are advancing in the clinic, highlighting emerging ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how ...

Psoriasis treatment has come a long way in the last 30 years. There’s no cure, but medication can help you gain control of your symptoms. If your current treatment doesn’t help enough, the doctor ...

Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient ...

Dupixent was approved in the U.S. as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria, the companies said on Wednesday. This expands the previous approval ...

Next-Gen Biologics Lead Healthcare InnovationThe Biologic Therapeutic Drug Market has emerged as one of the most ...